Skip to main content

Eli Lilly says obesity drug tirzepatide resulted in weight loss of up to 34 pounds

Eli Lilly plans to complete its application for FDA approval of tirzepatide in the coming weeks and expects regulatory action as early as later this year.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.